CALC Company Profile and Key Details

CalciMedica, Inc. (NASDAQ:CALC) closed at $6.13 USD, losing -$0.10 (-1.61%) from the previous close of $6.23. The stock is currently within 5% of its 52-week high $1.42 and $6.40. With a market capitalization of about $88.33 million, CalciMedica, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.12). Key stats such as the average daily volume over the past year has been around 72.96 thousand shares, in line with its 52-week average. Headquartered in La Jolla, CA, CalciMedica, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO A. Rachel Leheny, the company employs approximately 14 people and listed since June 14, 2023. CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs.

CALC has shown sold momentum, gaining 43.88% over the past week and 92.88% over the past quarter, though year-to-date performance is up 75.99%. Short-term trend indicators are bearishly aligned (SMA20 32.69%, SMA50 66.35%, SMA200 132.51%). The stock’s 14-day RSI is 75.2 (overbought), while the ATR of 0.46 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -2.66% below its high and over 338.73% above its low. Average 10-day trading volume of 130.96 thousand shares is significantly above the 3-month average of 73.11 thousand, indicating heightened recent market interest.

CalciMedica, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.71. This means the shares are trading above this model’s fair value.

CalciMedica, Inc. generated EPS of -$1.61 over the past year. Five-year average earnings growth is 47.54%. Wall Street analysts project EPS growth of -29.02% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $16.00. The high target offers 156.82% upside. The low target suggests 156.82% downside. The mean target is $16.00. This offers 156.82% upside. CalciMedica, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 1162.51%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -5.45% in August 12, 2024.

CalciMedica, Inc. has 13.97 million shares outstanding. The public float is 5.42 million shares, elevated short interest at 0.38% of float. This equals 35.59 thousand shares. The short ratio is 0.36 days. Institutional investors hold 70.21% of the float. Insiders own 16.76%. HOVDE ERIC D holds 1.43 million shares, WILSON ROBERT N has 422.03 thousand shares and Roberts Eric W has 84.15 thousand shares. Over the past six months, insider transactions show net buying. They sold 1.00 thousand shares across 1 transactions.

Our AI price prediction model suggests that CalciMedica, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 13.8%, with price expected at $7.09 by January 05, 2026, within a range of $6.79 to $7.37 3-Month Outlook: Projected fall of -27.77%, reaching $4.50 by March 20, 2026, with a range of $3.83 to $4.87. 1-Year Outlook: Projected gain of 367.42%, with price at $29.12 by December 22, 2026, within a range of $29.92 to $30.52.

CalciMedica, Inc. (NASDAQ:CALC) shares are up 75.99% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows CalciMedica, Inc. trading at a premium to the broader market with a P/E of -3955.44. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.86, suggesting 186.68% upside. Our AI forecast model points to short-term strength (13.8% over two weeks), a medium-term fall (-27.77% over three months), and a longer-term gain (367.42% over one year), with expected trading ranges indicating moderate volatility.